Hyundae Cho
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$18.3MFederal grants as PI28 awards
3Patents grantedLatest Oct 1, 2024
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
28 awards · $18.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Apr 24, 2025 | NIH | SBIR Phase II Point of Care HPV 16/18/45 DNA Test for Cervical Cancer | $994K | CROSSLIFE TECHNOLOGIES INC. |
| Sep 22, 2023 | NIH | SBIR Phase II Point of Care HPV 16/18/45 DNA Test for Cervical Cancer | $994K | CROSSLIFE TECHNOLOGIES INC. |
| Sep 18, 2023 | NIH | SBIR Phase II Point of Care HPV 16/18/45 DNA Test for Cervical Cancer | $994K | CROSSLIFE TECHNOLOGIES INC. |
| Aug 3, 2022 | NIH | SBIR Phase II Rapid Point-of-Care RNA Diagnostic for Dengue Infection | $1000K | CROSSLIFE TECHNOLOGIES INC. |
| Aug 13, 2021 | NIH | SBIR Phase II Rapid Point-of-Care RNA Diagnostic for Dengue Infection | $1000K | CROSSLIFE TECHNOLOGIES INC. |
| Aug 13, 2021 | NIH | SBIR Phase II Rapid Point-of-Care RNA Diagnostic for Dengue Infection | $2.0M | CROSSLIFE TECHNOLOGIES INC. |
| Jan 13, 2021 | NIH | SBIR Phase II Point-of-Care Rapid RNA test for Zika | $1000K | CROSSLIFE TECHNOLOGIES INC. |
| Aug 12, 2020 | NIH | SBIR Phase II Rapid, Point-of-Care Nucleic Acid Test for HCV | $990K | CROSSLIFE TECHNOLOGIES INC. |
| May 14, 2020 | NIH | SBIR Phase II Point of Care HPV 16/18/45 DNA Test for Cervical Cancer | $300K | CROSSLIFE TECHNOLOGIES INC. |
| Sep 15, 2019 | NIH | SBIR Phase II Rapid, Point-of-Care Nucleic Acid Test for HCV | $2.0M | CROSSLIFE TECHNOLOGIES INC. |
| Sep 12, 2019 | NIH | SBIR Phase II Rapid, Point-of-Care Nucleic Acid Test for HCV | $1000K | CROSSLIFE TECHNOLOGIES INC. |
| Jul 12, 2019 | NIH | SBIR Phase II Point-of-Care Rapid RNA test for HIV | $996K | CROSSLIFE TECHNOLOGIES INC. |
| Apr 11, 2019 | NIH | SBIR Phase II Rapid, Multiplexed Point-Of-Care Molecular Detection of Respiratory Pathogens without Sample Prep | $300K | CROSSLIFE TECHNOLOGIES INC. |
| Mar 14, 2019 | NIH | SBIR Phase II Rapid Point-of-Care RNA Diagnostic for Dengue Infection | $299K | CROSSLIFE TECHNOLOGIES INC. |
| Aug 27, 2018 | NIH | SBIR Phase II Point-of-Care Rapid RNA test for HIV | $1000K | CROSSLIFE TECHNOLOGIES INC. |
| Jun 1, 2017 | NSF | SBIR Phase I SBIR Phase I: Rapid, instrument-free Nucleic Acid Test for Pathogens and Biothreats | $225K | CROSSLIFE TECHNOLOGIES INC. |
| 2017 | NIH | SBIR Phase I A Rapid Paper Strip Nucleic Acid Test for the Point of Care Detection of Zika virus | $300K | CROSSLIFE TECHNOLOGIES INC. |
| Dec 27, 2016 | NIH | SBIR Phase I A Rapid Paper Strip Nucleic Acid Test for the Point of Care Detection of Zika virus | $300K | CROSSLIFE TECHNOLOGIES INC. |
| Jul 1, 2016 | NIH | SBIR Phase I A Rapid Paper Strip Nucleic Acid Test for the Detection of Chikungunya at the Point of Care | $282K | CROSSLIFE TECHNOLOGIES INC. |
| Jul 1, 2016 | NIH | SBIR Phase I Point-of-Care Rapid RNA test for HIV | $282K | CROSSLIFE TECHNOLOGIES INC. |
| Jul 1, 2016 | NIH | SBIR Phase I A Rapid Paper Strip Nucleic Acid Test for the Detection of Chikungunya at the Point of Care | $282K | CROSSLIFE TECHNOLOGIES INC. |
| Jun 30, 2016 | NIH | SBIR Phase I Point-of-Care Rapid RNA test for HIV | $282K | CROSSLIFE TECHNOLOGIES INC. |
| May 1, 2016 | NIH | SBIR Phase I Point-of-Care Rapid RNA Diagnosis of Influenza Virus | $307K | CROSSLIFE TECHNOLOGIES INC. |
| Apr 22, 2016 | NIH | SBIR Phase I Point-of-Care Rapid RNA Diagnosis of Influenza Virus | $307K | CROSSLIFE TECHNOLOGIES INC. |
| Mar 10, 2016 | NIH | SBIR Phase I Rapid Point-of-Care Diagnostic for Early Detection of Dengue Infection | $40K | CROSSLIFE TECHNOLOGIES INC. |
| May 20, 2015 | NIH | SBIR Phase I Rapid Point-of-Care Diagnostic for Early Detection of Dengue Infection | $345K | CROSSLIFE TECHNOLOGIES INC. |
| May 19, 2015 | NIH | SBIR Phase I Rapid Point-of-Care Diagnostic for Early Detection of Dengue Infection | $305K | CROSSLIFE TECHNOLOGIES INC. |
| — | NIH | SBIR Phase I Diagnostics to enable Malaria and Neglected Tropical Diseases | $216K | CROSSLIFE TECHNOLOGIES INC. |
4 patents as inventor
- US 10626447CROSSLIFE TECHNOLOGIES INC.Apr 21, 2020
- US 11685960CROSSLIFE TECHNOLOGIES INC.Jun 27, 2023
- US 12104201CROSSLIFE TECHNOLOGIES INC.Oct 1, 2024
- US CROSSLIFE TECHNOLOGIES INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#13
Awards as PI#8
Patents#124
Companies
- CROSSLIFE TECHNOLOGIES INC.Linked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.